CDEK
← All organizations

Jazz Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: Jazz | JAZZ | Jazz Pharamceuticals | Jazz Pharmaceuticals | Jazz Pharmaceuticals, Inc | Jazz Pharmaceuticals, Inc. | Jazz Pharmaceuticals Ireland Limited | JAZZ PHARMACEUTICALS IRELAND LIMITED | JAZZ PHARMS | JAZZ PHARMS III | JAZZ PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jan 1, 2003

First marketed drug

Jan 1, 2003

First NDA

Mar 20, 2019

Last known activity

Mar 1, 2026

Timeline

2000s

  1. Jan 1, 2003

    Jazz Pharmaceuticals— Founded

  2. Jan 1, 2005

    Orphan Medical— Acquired

2010s

  1. Nov 18, 2011

    erwinia asparaginase— NDA Secondary Org

  2. Nov 18, 2011

    erwinia asparaginase— Marketing Organization

  3. Jan 18, 2012

    Azur Pharma, Inc— Acquired

  4. Jan 18, 2012

    Azur Pharma PLC— Acquired

  5. Apr 26, 2012

    EUSA— Acquired

  6. Mar 31, 2014

    Gentium— Acquired

  7. May 31, 2016

    Celator PharmaceuticalsCelator Pharmaceuticals— Acquired

  8. Aug 12, 2019

    Cavion LLC— Acquired

2020s

  1. Jun 15, 2020

    lurbinectedin— NDA Organization

  2. Feb 3, 2021

    Greenwich Biosciences— Acquired

  3. Feb 3, 2021

    GW Pharmaceuticals Ltd.— Acquired

  4. Mar 5, 2025

    Chimerix— Acquired

Drugs by trial phase (121 distinct, 248 trials)

Indications

Studied for

Marketed drugs (15)

Subsidiaries (10 direct, 14 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Dublin, IE Jan 1, 2003
First NDA
Mar 20, 2019
Last known activity
Mar 1, 2026

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy
  • Accelerated approval